Literature DB >> 4064609

Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.

H C Neu, P Labthavikul.   

Abstract

The in vitro activity of amifloxacin, a quinolone antimicrobial agent was compared with those of ciprofloxacin, enoxacin, ofloxacin and norfloxacin against gram-positive and gram-negative bacteria. Ninety percent of Escherichia coli, Klebsiella species, Aeromonas, Salmonella, Shigella, Citrobacter, Enterobacter species, Proteus mirabilis, Serratia marcescens, and Morganella morganii were inhibited by less than or equal to 0.5 microgram/ml. Amifloxacin inhibited Branhamella, Haemophilus, and Neisseria at less than or equal to 0.25 microgram/ml, and 90% of Pseudomonas aeruginosa, including gentamicin- and carbenicillin-resistant isolates, at 4 micrograms/ml. It also inhibited staphylococci, including methicillin-resistant isolates, but was less active against streptococci and Bacteroides species. Amifloxacin had in vitro activity similar to enoxacin, ofloxacin, and norfloxacin, but was less active than ciprofloxacin. Like other quinolones, it was less active at acid pH and in the presence of urine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4064609     DOI: 10.1016/s0732-8893(85)80003-1

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  5 in total

1.  Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers.

Authors:  J A Cook; M H Silverman; D J Schelling; D E Nix; J J Schentag; R R Brown; R M Stroshane
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. Amifloxacin Multi-Center Trial Group.

Authors:  E J Boyko; A Iravani; M H Silverman; D J Schelling; R A Wright
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Preliminary study of the pharmacokinetics of oral amifloxacin in elderly subjects.

Authors:  R M Stroshane; M H Silverman; R Sauerschell; R R Brown; A W Boddy; J A Cook
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

4.  Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.

Authors:  A L Barry; R N Jones
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

Review 5.  Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Monk; D M Campoli-Richards
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.